Biosimilar SB12 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups.

Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a biosimilar to Soliris 1, in paroxysmal nocturnal hemoglobinuria (PNH) at the ...

It is estimated that approximately 10-20 people per million worldwide live with PNH. 2 Although PNH can develop at any age, it is often diagnosed in people between 30-40 years old. 1516 ...

Paroxysmal nocturnal hemoglobinuria (PNH) affects your bone marrow, where your body makes new blood cells. It can be hard to diagnose. For one thing, it's rare. And its symptoms look like those of ...

Paroxysmal nocturnal hemoglobinuria (PNH) and aplastic anemia (AA) are both rare disorders in their own right, but in some patients, they overlap, representing a unique medical challenge. Studies ...

In some cases, a bone marrow transplant may be necessary, especially if PNH is accompanied by other bone marrow disorders. Regular monitoring and supportive care are also essential, as they can ...

Fabhalta® is the first oral monotherapy for previously treated and treatment-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH)1,2 Significant unmet need remains in PNH, a chronic, rare ...

PNH is an ultra-rare and debilitating blood disease that causes red blood cells to fragment, in addition to thrombophilia and bone marrow failure.

Bone marrow transplantation is the only cure for PNH. However, it can cause severe complications and even death and is reserved only for very severe cases of PNH. Complement inhibitors.

Patients with PNH often derive benefits from C5is like ravulizumab and eculizumab; however, as the present authors note, these patients may still struggle with chronic anemia. 1 By starting ...

As, for example, bone marrow can be severely impacted in patients with PNH, developing a more comprehensive understanding of the disease can help guide and inform earlier interventions to combat ...

The factor D inhibitor danicopan has been approved for use in Europe for patients with paroxysmal nocturnal hemoglobinuria with residual hemolytic anemia on standard therapy.